Clinical Trial Update: DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity [Phase 3]

View source ↗

Summary

Phase 3 trial comparing DOR/TDF/3TC with BIC/FTC/TAF in ART-naïve people living with HIV who are overweight or obese; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Obesity

Drugs mentioned

• Bictegravir (bictegravir)
• Doravirine (doravirine)
• Emtricitabine (Emtricitabine)
• Lamivudine (lamivudine)
• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)
• Tenofovir alafenamide (tenofovir alafenamide)

Snippet

Sponsor: José Antonio Mata Marín | Conditions: HIV - Human Immunodeficiency Virus, Obesity | Phase 3 | Status: RECRUITING